US Regulators Approve ‘Game-Changing’ Type 1 Diabetes Drug

Type 1 diabetes affects about 8.7 million people around the world.
Illustration shows syringes with small doses of insulin for a diabetes patient, in Hasselt, Wednesday 14 September 2022. Media reports that another insulin incident took place in May 2022 at an elderly home in Hasselt. Only last week, reports came of incidents in Oostrozebeke, where several elderly residents from elderly home Rozenberg were injected with an overdose of insulin, last year. Three times that resulted in a murder. In the case of four other victims, it remained an attempt. 
BELGA PHOTO JILL DELSAUX (Photo by JILL DELSAUX / BELGA MAG / Belga via AFP) (Photo by JILL DELSAUX/BELGA MAG/AFP via Getty Images)

At a glance

  • A new immunotherapy drug that delays the development of type 1 diabetes was given the green light by U.S. regulators.
  • Teplizumab focuses on addressing the root cause of the condition, rather than the symptoms, which experts say ushers in a “new era” in treatment.
  • The drug works by reprogramming the body’s immune system and preventing it from mistakenly attacking pancreatic cells, which produce insulin.

Top News Stories

Sponsored